Aura Biosciences (AURA) Non-Current Deffered Revenue (2020)

Aura Biosciences (AURA) posted Non-Current Deffered Revenue of $8000.0 for Q4 2020.

Aura Biosciences (AURA) Non-Current Deffered Revenue (2020) Analysis & Trends

Aura Biosciences' Non-Current Deffered Revenue history runs 1 years deep, the most recent figure standing at $8000.0 for Q4 2020.

Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $8000.0 in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $8000.0 (changed N/A YoY) and the FY2020 annual result came in at $8000.0, changed N/A from the prior year.
Non-Current Deffered Revenue was $8000.0 for Q4 2020 at Aura Biosciences.
Across five years, Non-Current Deffered Revenue topped out at $8000.0 in Q4 2020 and bottomed at $8000.0 in Q4 2020.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Non-Current Deffered Revenue (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	-
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	225.10 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Aura Biosciences	485.62 Mn	400.83 Mn	-	-

Historic Data

Download Data

Date	Value
Dec 31, 2020	8,000.00